All In Biotech

Drug Trial Radar · NCT06194500

A Study of Carbon-14-Labeled [14C]-LY3549492 in Healthy Participants

An Open-label, Two-part Study of the Disposition and Absolute Bioavailability of [14C]-LY3549492 in Healthy Participants

Last checked: Nov 19, 2026Latest source record: Mar 28, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

18

Actual

Start

Jan 3, 2024

Primary completion

Feb 15, 2024

Study completion Feb 15, 2024

Sponsor

Lead sponsor
Eli Lilly and CompanyEli Lilly (LLY)
Sponsor type
Industry
First posted
Jan 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
Male only, from 35 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The main purpose of this study is to measure how much of the study drug gets into the bloodstream and how long it takes the body to get rid of it. This study will be conducted in healthy males and has two parts. In Part A, participants will receive carbon-14 (14C) radiolabeled LY3549492 (\[14C\] LY3549492) given by mouth. In Part B, participants will receive LY3549492 by mouth. Three hours later, participants will receive \[14C\] LY3549492 given into a vein. The radioactive substance C14 will be incorporated into the study drug to investigate the study drug and breakdown products to find out how much of these passes from blood into urine, stool, and breath. The study will last about 2 months in Part A and about 1½ months in Part B. This includes screening, treatment, and follow-up visits.

Conditions

  • Healthy Male

Interventions

  • [14C]-LY3549492Drug

    Administered as oral solution.

  • LY3549492Drug

    Administered orally.

  • [14C]-LY3549492Drug

    Administered as IV infusion.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Urinary Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose in Part ATime frame: Predose up to Day 24 postdose in Part A
  2. Fecal Excretion of Total Radioactivity Over Time Expressed as a Percentage of the Total Radioactive Dose in Part ATime frame: Predose up to Day 24 postdose in Part A
  3. Pharmacokinetic (PK): Area Under the Curve (AUC) for Oral Determination of Absolute Bioavailability (F) of LY3549492 in Part BTime frame: Predose up to Day 7 postdose in Part B
  4. PK: AUC for Intravenous (IV) Determination of Absolute Bioavailability (F) of LY3549492 in Part BTime frame: Predose up to Day 7 postdose in Part B

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fortrea Clinical Research Unit

    Holbeck, Leeds, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.